NCT05566223 2026-02-23
CheckCell-2
Intima Bioscience, Inc.
Phase 1/2 Withdrawn
Clinical Trials
12 trialsNCT05705466 2024-03-22
Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer
Kartos Therapeutics, Inc.
Phase 1/2 Withdrawn
NCT05791097 2023-07-24
AdvanTIG-306
Novartis
Phase 3 Withdrawn
NCT05171062 2023-07-20
Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer
The University of Texas Health Science Center at San Antonio
Phase 1 Withdrawn
NCT05234606 2022-04-12
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
Silverback Therapeutics
Phase 1/2 Withdrawn
NCT04754815 2022-03-29
HFHS 21-01
Henry Ford Health System
Phase 2 Withdrawn
NCT04061590 2022-03-04
Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer
University of California, San Francisco
Phase 2 Withdrawn
NCT03245177 2021-07-28
PARIS
The Christie NHS Foundation Trust
Phase 1 Withdrawn
NCT03574220 2020-04-07
Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Withdrawn
NCT04158700 2020-02-19
A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1/2 Withdrawn
NCT03311672 2019-10-21
T-Cell PET Imaging With [18F]F-AraG in Lung Cancer
University of California, San Francisco
Phase 2 Withdrawn
NCT03166254 2019-04-12
Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab and Standard of Care Chemotherapy in Squamous Non-Small Cell Lung Cancer and Extensive Stage Small Cell Lung Cancer
Washington University School of Medicine
Phase 1 Withdrawn